Incyte Corporation

(INCY) Trade

By |

Profile

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant, which Eli Lilly licenses, and oncology drug Iclusig for chronic myeloid leukemia. Incyte's pipeline includes a broad array of oncology and autoimmune programs, including next-generation JAK inhibitor itacitinib.

Contact Information

Website: www.incyte.com
Email: mbooth@incyte.com
Main Phone: +1 302 498-6700
Address: 1801 Augustine Cut-Off
State: DE
City / Town: Wilmington
Country: USA
Postal Code: 19803

Issuer Information

Exchange: NGS
CEO: Herve Hoppenot
Employees: 1208
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)(541714)


Gathering Data... Please wait

Profile

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant, which Eli Lilly licenses, and oncology drug Iclusig for chronic myeloid leukemia. Incyte's pipeline includes a broad array of oncology and autoimmune programs, including next-generation JAK inhibitor itacitinib.

Contact Information

Website: www.incyte.com
Email: mbooth@incyte.com
Main Phone: +1 302 498-6700
Address: 1801 Augustine Cut-Off
State: DE
City / Town: Wilmington
Country: USA
Postal Code: 19803

Issuer Information

Exchange: NGS
CEO: Herve Hoppenot
Employees: 1208
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)(541714)
$ 84.15 $ 0.73 (0.88%)
Last Price 84.15 Change $ 0.73 Change % 0.88 Tick N/A
Bid 75.00 Bid Size 100.00 Ask 84.99 Ask Size 100.00
Open 82.05 High 84.25 Low 82.05 Prev Close 83.42
Last Trade Volume 1.9 mi 52 Wk Hi 96.33 52 Wk Low 57.00
Market Cap 17.9 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 212,808,148.00 EPS (TTM) -0.53 PE Ratio N/A Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 19 111
Number of Buys 16 65
Number of Sells 3 46
Net Activity 116488 97819
Last 10 Buys Shares
Herve Hoppenot 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Jean-Jacques Bienaime 1,000
Jean-Jacques Bienaime 1,000
Jean-Jacques Bienaime 1,000
Jean-Jacques Bienaime 1,000
Jean-Jacques Bienaime 1,000
Julian C. Baker 1,000
Last 10 Sell Shares
Paula J. Swain 1,000
Paula J. Swain 1,000
David W. Gryska 1,000
Reid M. Huber 1,000
David W. Gryska 1,000
Vijay K. Iyengar 1,000
Reid M. Huber 1,000
Paul A. Friedman 1,000
David W. Gryska 1,000
Herve Hoppenot 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 148 148 148 148
Low Target Price Estimate 65 65 65 65
Mean Target Price Estimate 96.38 97.13 97.13 96.38
Standard Deviation 28.29 29.11 29.11 28.29
Date of Most Recent Estimate 06/02/18 05/09/18 05/09/18 06/07/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 12 10 10 12
Moderate Buy 3 3 3 3
Hold 4 5 5 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.55 1.69 1.69 1.55